A listing of Immune Thrombocytopenia (ITP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg …